Whitehawk Therapeutics Q2 net loss narrows to $16.6 million from $52.6 million
Whitehawk Therapeutics reported a second-quarter 2026 net loss of $16.6 million, down from $52.6 million a year earlier, as research and development spending fell to $12.9 million from $48.8 million. The company said cash, cash equivalents and short-term investments were $190.0 million at June 30, 2026, which it expects to fund operations into 2H 2028.
Key points
- Net loss per share was $0.20 in Q2 2026 versus $0.76 in Q2 2025.
- R&D expenses were $12.9 million versus $48.8 million; the prior-year quarter included a $38.0 million up-front license fee paid to WuXi Biologics.
- Cash, cash equivalents and short-term investments totaled $190.0 million at June 30, 2026, including proceeds from an $87.5 million private placement announced in May 2026.
- The company reported no revenue in either Q2 2026 or Q2 2025.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.